Here’s what you should know.
1. Penn State identified genes that predict a higher colorectal cancer probability. By matching the genes to patients, the university’s providers can take preventative measures to mitigate colorectal cancer risk.
2. Providers can also alter treatments to respond better to a patient’s genetics.
Biobank Director Walter Koltun, MD, said, “With some colorectal cancers, some genes dictate which patients will do better with chemotherapy or not. That’s how some of the genetic data is being utilized for patient management.”
3. The biobank has been collecting tissue samples since 1998. The center currently holds approximately 3,000 samples, which allows researchers to study colorectal cancer’s biological pathways.
4. The biobank offers patients an unintended benefit as well. It allows providers to show patients developing the disease due to their genetics.
More articles on gastroenterology:
GI leader to know: Dr. Katie Agnello of Florida Digestive Health Specialists
Loyola Medicine offering PillCam Colon 2 treatment: 4 insights
Gastroenterology leaders spreading colorectal cancer awareness: 3 key notes
